The utilization of chromosomal microarray technologies for hematologic neoplasms: An ACLPS critical review

Jess F. Peterson, Daniel L. Van Dyke, Nicole L. Hoppman, Hutton M. Kearney, William R. Sukov, Patricia T Greipp, Rhett P. Ketterling, Linda Baughn

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objectives: Chromosome (G-banding) and fluorescence in situ hybridization (FISH) serve as the primary methodologies utilized for detecting genetic aberrations in hematologic neoplasms. Chromosomal microarray can detect copy number aberrations (CNAs) with greater resolution when compared to G-banding and FISH, and can also identify copy-neutral loss of heterozygosity (CN-LOH). The purpose of our review is to highlight a preselected group of hematologic neoplasms for which chromosomal microarray has the greatest clinical utility. Methods: A case-based approach and review of the literature was performed to identify the advantages and disadvantages of utilizing chromosomal microarray for specific hematologic neoplasms. Results: Chromosomal microarray identified CNAs and CN-LOH of clinical significance, and could be performed on fresh or paraffin-embedded tissue and liquid neoplasms. Microarray studies could not detect balanced rearrangements, low-level clones, or distinguish independent clones. Conclusions: When utilized appropriately, chromosomal microarray can provide clinically significant information that complements traditional cytogenetic testing methodologies.

Original languageEnglish (US)
Pages (from-to)375-384
Number of pages10
JournalAmerican Journal of Clinical Pathology
Volume150
Issue number5
DOIs
StatePublished - Oct 1 2018

Fingerprint

Hematologic Neoplasms
Loss of Heterozygosity
Technology
Fluorescence In Situ Hybridization
Clone Cells
Chromosomes, Human, 21-22 and Y
Chromosome Banding
Cytogenetics
Paraffin
Neoplasms

Keywords

  • Array-based comparative genomic hybridization (aCGH)
  • Chromosomal microarray
  • Hematologic neoplasms
  • Single nucleotide polymorphism (SNP)

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

The utilization of chromosomal microarray technologies for hematologic neoplasms : An ACLPS critical review. / Peterson, Jess F.; Van Dyke, Daniel L.; Hoppman, Nicole L.; Kearney, Hutton M.; Sukov, William R.; Greipp, Patricia T; Ketterling, Rhett P.; Baughn, Linda.

In: American Journal of Clinical Pathology, Vol. 150, No. 5, 01.10.2018, p. 375-384.

Research output: Contribution to journalArticle

Peterson, Jess F. ; Van Dyke, Daniel L. ; Hoppman, Nicole L. ; Kearney, Hutton M. ; Sukov, William R. ; Greipp, Patricia T ; Ketterling, Rhett P. ; Baughn, Linda. / The utilization of chromosomal microarray technologies for hematologic neoplasms : An ACLPS critical review. In: American Journal of Clinical Pathology. 2018 ; Vol. 150, No. 5. pp. 375-384.
@article{d13e32e1898e417eb216d134bbab3c55,
title = "The utilization of chromosomal microarray technologies for hematologic neoplasms: An ACLPS critical review",
abstract = "Objectives: Chromosome (G-banding) and fluorescence in situ hybridization (FISH) serve as the primary methodologies utilized for detecting genetic aberrations in hematologic neoplasms. Chromosomal microarray can detect copy number aberrations (CNAs) with greater resolution when compared to G-banding and FISH, and can also identify copy-neutral loss of heterozygosity (CN-LOH). The purpose of our review is to highlight a preselected group of hematologic neoplasms for which chromosomal microarray has the greatest clinical utility. Methods: A case-based approach and review of the literature was performed to identify the advantages and disadvantages of utilizing chromosomal microarray for specific hematologic neoplasms. Results: Chromosomal microarray identified CNAs and CN-LOH of clinical significance, and could be performed on fresh or paraffin-embedded tissue and liquid neoplasms. Microarray studies could not detect balanced rearrangements, low-level clones, or distinguish independent clones. Conclusions: When utilized appropriately, chromosomal microarray can provide clinically significant information that complements traditional cytogenetic testing methodologies.",
keywords = "Array-based comparative genomic hybridization (aCGH), Chromosomal microarray, Hematologic neoplasms, Single nucleotide polymorphism (SNP)",
author = "Peterson, {Jess F.} and {Van Dyke}, {Daniel L.} and Hoppman, {Nicole L.} and Kearney, {Hutton M.} and Sukov, {William R.} and Greipp, {Patricia T} and Ketterling, {Rhett P.} and Linda Baughn",
year = "2018",
month = "10",
day = "1",
doi = "10.1093/ajcp/aqy076",
language = "English (US)",
volume = "150",
pages = "375--384",
journal = "American Journal of Clinical Pathology",
issn = "0002-9173",
publisher = "American Society of Clinical Pathologists",
number = "5",

}

TY - JOUR

T1 - The utilization of chromosomal microarray technologies for hematologic neoplasms

T2 - An ACLPS critical review

AU - Peterson, Jess F.

AU - Van Dyke, Daniel L.

AU - Hoppman, Nicole L.

AU - Kearney, Hutton M.

AU - Sukov, William R.

AU - Greipp, Patricia T

AU - Ketterling, Rhett P.

AU - Baughn, Linda

PY - 2018/10/1

Y1 - 2018/10/1

N2 - Objectives: Chromosome (G-banding) and fluorescence in situ hybridization (FISH) serve as the primary methodologies utilized for detecting genetic aberrations in hematologic neoplasms. Chromosomal microarray can detect copy number aberrations (CNAs) with greater resolution when compared to G-banding and FISH, and can also identify copy-neutral loss of heterozygosity (CN-LOH). The purpose of our review is to highlight a preselected group of hematologic neoplasms for which chromosomal microarray has the greatest clinical utility. Methods: A case-based approach and review of the literature was performed to identify the advantages and disadvantages of utilizing chromosomal microarray for specific hematologic neoplasms. Results: Chromosomal microarray identified CNAs and CN-LOH of clinical significance, and could be performed on fresh or paraffin-embedded tissue and liquid neoplasms. Microarray studies could not detect balanced rearrangements, low-level clones, or distinguish independent clones. Conclusions: When utilized appropriately, chromosomal microarray can provide clinically significant information that complements traditional cytogenetic testing methodologies.

AB - Objectives: Chromosome (G-banding) and fluorescence in situ hybridization (FISH) serve as the primary methodologies utilized for detecting genetic aberrations in hematologic neoplasms. Chromosomal microarray can detect copy number aberrations (CNAs) with greater resolution when compared to G-banding and FISH, and can also identify copy-neutral loss of heterozygosity (CN-LOH). The purpose of our review is to highlight a preselected group of hematologic neoplasms for which chromosomal microarray has the greatest clinical utility. Methods: A case-based approach and review of the literature was performed to identify the advantages and disadvantages of utilizing chromosomal microarray for specific hematologic neoplasms. Results: Chromosomal microarray identified CNAs and CN-LOH of clinical significance, and could be performed on fresh or paraffin-embedded tissue and liquid neoplasms. Microarray studies could not detect balanced rearrangements, low-level clones, or distinguish independent clones. Conclusions: When utilized appropriately, chromosomal microarray can provide clinically significant information that complements traditional cytogenetic testing methodologies.

KW - Array-based comparative genomic hybridization (aCGH)

KW - Chromosomal microarray

KW - Hematologic neoplasms

KW - Single nucleotide polymorphism (SNP)

UR - http://www.scopus.com/inward/record.url?scp=85054061256&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054061256&partnerID=8YFLogxK

U2 - 10.1093/ajcp/aqy076

DO - 10.1093/ajcp/aqy076

M3 - Article

C2 - 30052716

AN - SCOPUS:85054061256

VL - 150

SP - 375

EP - 384

JO - American Journal of Clinical Pathology

JF - American Journal of Clinical Pathology

SN - 0002-9173

IS - 5

ER -